会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • E1-revertant-free adenoviral composition
    • E1无反应蛋白腺病毒组合物
    • US20040209247A1
    • 2004-10-21
    • US10844133
    • 2004-05-12
    • GenVec, Inc.
    • Douglas E. BroughImre Kovesdi
    • C12Q001/70
    • C12N15/86A61K48/00C12N2710/10343
    • The invention provides a composition comprising particles of an adenoviral vector comprising deficiencies in two or more gene functions required for viral replication, wherein at least one of the deficiencies is of a gene function of the E1 region of the adenoviral genome and (b) a carrier therefor, with relatively high ratios of (i) the number of particles of the adenoviral vectors to the number of particles of E1-revertant replication-deficient adenoviral vectors not comprising one or more of the deficiencies in gene functions of the E1 region of the adenoviral and (ii) the number of particles of the adenoviral vectors to the number of particles of replication-competent adenoviral vectors, as well as a method of preparing such a composition.
    • 本发明提供包含腺病毒载体颗粒的组合物,其包含病毒复制所需的两个或更多个基因功能的缺陷,其中至少一个缺陷是腺病毒基因组的E1区域的基因功能,和(b)载体 因此,具有相对高的比例(i)腺病毒载体的颗粒数与E1复发缺失型复制缺陷型腺病毒载体的颗粒数量不包含腺病毒E1区的基因功能的一个或多个缺陷 和(ii)腺病毒载体的颗粒数与复制能力的腺病毒载体的颗粒数目,以及制备这种组合物的方法。
    • 3. 发明申请
    • Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
    • 使用反式激活和CIS激活来调节至少E4缺陷型腺病毒中转基因表达的持久性
    • US20010010933A1
    • 2001-08-02
    • US09771832
    • 2001-01-29
    • GenVec, Inc.
    • Douglas E. BroughImre Kovesdi
    • A61K048/00C12N015/09C12N007/01
    • C12N15/86C07K14/005C12N15/63C12N2710/10322C12N2710/10345C12N2710/16622C12N2830/60C12N2840/60
    • The present invention provides a method of modulating the persistence of expression of a transgene in an at least E4null adenoviral vector in a cell. In one embodiment, the method comprises contacting the cell with an at least E4null adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In another embodiment, the method comprises contacting the cell simultaneously or sequentially with (i) an at least E4null adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In addition, the present invention provides a recombinant at least E4null adenoviral vector for use in the method and a composition comprising the vector and a carrier therefor. Also provided by the present invention is a system for modulation of a recombinant at least E4null adenoviral vector for use in the method and a composition comprising the system and a carrier therefor.
    • 本发明提供了调节细胞中至少E4DELTA腺病毒载体中转基因表达的持久性的方法。 在一个实施方案中,该方法包括使细胞与至少E4DELTA腺病毒载体接触,所述载体包含(i)转基因和(ii)编码反式作用因子的基因,其不是来自腺病毒的E4区域,并且其调节 持续表达的转基因。 在另一个实施方案中,该方法包括使细胞同时或顺序地与(i)包含转基因的至少E4DELTA腺病毒载体接触,和(ii)包含编码反作用因子的基因的病毒载体,其不是来自E4区 的腺病毒,并且其调节转基因表达的持续性。 此外,本发明提供了用于该方法的重组至少E4DELTA腺病毒载体和包含载体及其载体的组合物。 本发明还提供了一种用于调节用于该方法的重组至少E4DELTA腺病毒载体的系统和包含该系统和其载体的组合物。
    • 5. 发明申请
    • Plasmids for construction of eukaryotic viral vectors
    • 用于构建真核病毒载体的质粒
    • US20020004242A1
    • 2002-01-10
    • US09905758
    • 2001-07-13
    • GenVec, Inc.
    • Duncan L. McVeyDouglas E. BroughImre Kovesdi
    • C12N015/86C07H021/04
    • C12N15/86C12N15/65C12N2710/10343C12N2800/30C12N2830/001C12N2830/15C12N2830/55
    • The present invention provides a dual selection cassette (DSC) comprising first and second DNA segments having homology to a eukaryotic viral vector, positive and negative selection genes, each operably linked to their own promoter, and one or more unique restriction enzyme sites (URES) or sitey-directed homologous recombination sites. The present invention also provides a plasmid, pN/P, comprising an independent positive selection marker gene, an origin of replication, and a dual selection cassette. The dual selection cassette and pN/P plasmid can be used to produce eukaryotic gene transfer vectors without requiring temporally-linked double recombination events or the use of specialized bacterial strains that allow the replication of plasmids comprising defective origins of replication. This method usefully increases the ratio of desired to undesired plasmid and vector constructs. Additionally, this invention provides a method for the creation of eukaryotic viral vector libraries.
    • 本发明提供了一种双重选择盒(DSC),其包含与真核病毒载体具有同源性的第一和第二DNA片段,每个与其本身的启动子可操作地连接的阳性和阴性选择基因,以及一个或多个独特的限制酶位点(URES) 或定点同源重组位点。 本发明还提供了包含独立的阳性选择标记基因,复制起点和双选择盒的质粒pN / P。 双选择盒和pN / P质粒可用于产生真核基因转移载体,而不需要时间连接的双重重组事件或使用允许复制包含有缺陷复制起点的质粒的专门细菌菌株。 该方法有效地增加了期望的和不需要的质粒和载体构建体的比例。 此外,本发明提供了一种用于产生真核病毒载体文库的方法。
    • 8. 发明申请
    • E1-revertant-free adenoviral composition
    • E1无反应蛋白腺病毒组合物
    • US20030087438A1
    • 2003-05-08
    • US10001097
    • 2001-11-02
    • GenVec, Inc.
    • Douglas E. BroughImre Kovesdi
    • A61K048/00C12N015/861C12N007/02C12N007/00
    • C12N15/86A61K48/00C12N2710/10343
    • The invention provides a composition comprising particles of an adenoviral vector comprising deficiencies in two or more gene functions required for viral replication, wherein at least one of the deficiencies is of a gene function of the E1 region of the adenoviral genome and (b) a carrier therefor, with relatively high ratios of (i) the number of particles of the adenoviral vectors to the number of particles of E1-revertant replication-deficient adenoviral vectors not comprising one or more of the deficiencies in gene functions of the E1 region of the adenoviral and (ii) the number of particles of the adenoviral vectors to the number of particles of replication-competent adenoviral vectors, as well as a method of preparing such a composition.
    • 本发明提供包含腺病毒载体颗粒的组合物,其包含病毒复制所需的两个或多个基因功能的缺陷,其中至少一个缺陷是腺病毒基因组的E1区域的基因功能,和(b)载体 因此,具有相对高的比例(i)腺病毒载体的颗粒数与E1复发缺失型复制缺陷型腺病毒载体的颗粒数量不包含腺病毒E1区的基因功能的一个或多个缺陷 和(ii)腺病毒载体的颗粒数与复制能力的腺病毒载体的颗粒数目,以及制备这种组合物的方法。
    • 9. 发明申请
    • Materials and methods for treating ocular-related disorders
    • 用于治疗眼部相关疾病的材料和方法
    • US20030045498A1
    • 2003-03-06
    • US10211701
    • 2002-08-02
    • GenVec, Inc.
    • Imre KovesdiDouglas E. BroughLisa WeiDuncan L. McVey
    • A61K048/00C12N015/85
    • C12N15/86A61K48/00A61K48/005A61K48/0075C07K14/71C07K14/811C12N2710/10343C12N2799/022
    • The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.
    • 本发明涉及一种预防性或治疗性地治疗动物至少一种与眼部相关的疾病,例如眼睛新生血管形成或年龄相关性黄斑变性的方法。 该方法包括使眼细胞与包含编码血管生成抑制剂的核酸序列和编码神经营养剂的相同或不同核酸序列的表达载体接触。 该方法还可以包括使眼细胞与不同的表达载体接触,每种表达载体包含编码血管生成抑制剂的核酸序列和/或编码神经营养剂的核酸序列。 此外,本发明提供了包含编码色素上皮衍生因子(PEDF)的核酸序列或其治疗片段的病毒载体。